[Asia Economy Reporter Ji Yeon-jin] Bioinfra Life Sciences (CEO Lee Deok-yoon) announced on the 27th that it has signed an exclusive license agreement in the United States with 20/20 GeneSystems for the in vitro cancer diagnostic technology 'i-FINDER'.
i-FINDER is a test that screens high-risk groups for eight types of cancer (lung, liver, stomach, colorectal, pancreatic, prostate, breast, and ovarian cancer) with a single blood test. This technology includes an optimized panel of multiple biomarkers and algorithms that improve diagnostic accuracy, allowing the assessment of risk for individual cancer types rather than overall cancer risk.
Through this agreement, Bioinfra Life Sciences will receive both upfront license royalties and running royalties.
CEO Lee Deok-yoon stated, "Recently, President Joe Biden signed executive orders focusing on domestic production of key industries such as bio and pharmaceuticals, following the Inflation Reduction Act and the Semiconductor Act, and support policies are expected to continue. We believe that entering the U.S. market through a local U.S. company supported by the government, rather than directly providing services ourselves, will align with U.S. bio-related policies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
